Table of contents
November 2006 - Volume 65 - suppl 3
Advances in targeted therapies VIII
- Preface
- Consensus statement
- Recent aspects in outcome research
- Animal models
- Regulatory T cells and tolerance induction: ready for the clinic?
- Pharmacoeconomics and updates on current and imminent therapeutics
- The risks of targeted therapies
- Novel targets I
- Short presentations
- Novel targets III
- Novel targets V
- Epilogue
Preface
- Advances in targeted therapies VIII (12 October, 2006)
Consensus statement
Recent aspects in outcome research
Animal models
Regulatory T cells and tolerance induction: ready for the clinic?
- Role of nitric oxide in the regulation of T cell functions (12 October, 2006)
- Can studies of tolerance ever lead to therapy? (12 October, 2006)
Pharmacoeconomics and updates on current and imminent therapeutics
- Pharmacoeconomics: friend or foe? (12 October, 2006)
The risks of targeted therapies
- Natalizumab and progressive multifocal leucoencephalopathy (12 October, 2006)
- Serious infections with antirheumatic therapy: are biologicals worse? (12 October, 2006)
- Treating rheumatic diseases in pregnancy: dos and don’ts (12 October, 2006)
Novel targets I
- IL-32, a novel cytokine with a possible role in disease (12 October, 2006)
- Heat shock proteins induce T cell regulation of chronic inflammation (12 October, 2006)
Short presentations
- Interleukin-7 induced immunopathology in arthritis (12 October, 2006)
Novel targets III
- Use of cell permeable NBD peptides for suppression of inflammation (12 October, 2006)
Novel targets V
Epilogue
- Targeted therapies: summary clinical trials working group (12 October, 2006)